{
  "meta": {
    "title": "69_Pulmonary_Hypertension",
    "url": "https://brainandscalpel.vercel.app/69-pulmonary-hypertension-c0ffbdaa.html",
    "scrapedAt": "2025-11-30T12:29:00.743Z"
  },
  "questions": [
    {
      "text": "A patient with a history of frequent exacerbations of COPD is undergoing right heart catheterization for evaluation of pulmonary artery pressure. What is the mean pulmonary arterial pressure above which the diagnosis of pulmonary hypertension can be made?",
      "choices": [
        {
          "id": 1,
          "text": ">20 mmHg"
        },
        {
          "id": 2,
          "text": ">25 mmHg"
        },
        {
          "id": 3,
          "text": ">32 mmHg"
        },
        {
          "id": 4,
          "text": "> 30 mmHg"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Pulmonary hypertension</strong> is a pathological hemodynamic condition characterized by a mean pulmonary arterial pressure (<strong>mPAP</strong>)<strong>&nbsp;&gt;20mmHg&nbsp;</strong>assessed by right heart catheterization.</p>\n<p>Pulmonary hypertension could be a <strong>complication</strong> of <strong>cardiac</strong> or <strong>pulmonary</strong> disease or a primary disorder of small pulmonary arteries. <strong>Right heart catheterization</strong> is the<strong> gold standard </strong>investigation in diagnosing pulmonary hypertension.<br /><br />Note:&nbsp;The threshold for diagnosing pulmonary hypertension has been <strong>revised</strong> from &gt;<strong>25</strong> mmHg to &gt;<strong>20</strong> mmHg to enable earlier detection.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3723",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following genes is the most commonly implicated in hereditary pulmonary arterial hypertension?",
      "choices": [
        {
          "id": 1,
          "text": "Endothelin"
        },
        {
          "id": 2,
          "text": "PAX – 11"
        },
        {
          "id": 3,
          "text": "Bone morphogenetic protein receptor 2"
        },
        {
          "id": 4,
          "text": "Homebox gene"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Bone morphogenetic protein receptor 2<strong> (BMPR2) mutation</strong> is&nbsp;the most commonly implicated gene in <strong>hereditary</strong> pulmonary arterial hypertension (<strong>PAH</strong>).</p>\n<p>The BMPR2 receptor is involved in the regulation of growth, differentiation, and apoptosis of pulmonary artery endothelial and smooth muscle cells. Due to the mutation, there is enhanced proliferation and reduced apoptosis of vascular endothelial and smooth muscle cells leading to pulmonary hypertension.</p><hr><h3>Related Pearl: Classification of Pulmonary Hypertension & its Causes</h3><p>Based on underlying mechanisms, the World Health Organization has classified pulmonary hypertension into five groups.</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Classification</strong></p>\n</td>\n<td>\n<p><strong>Causes</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Group 1</strong></p>\n<p><strong>Pulmonary arterial hypertension (PAH)</strong></p>\n</td>\n<td>\n<p>Idiopathic PAH</p>\n<p>Hereditary PAH - BMPR2 gene (most common mutation)</p>\n<p>Drug or toxin-induced PAH</p>\n<p>PAH associated with</p>\n<ul>\n<li>Connective tissue disorder (limited systemic sclerosis)</li>\n<li>Portal hypertension</li>\n<li>HIV</li>\n<li>Schistosomiasis</li>\n<li>Congenital heart diseases</li>\n</ul>\n<p>PAH long-term responders to calcium channel blockers</p>\n<p>PAH with overt features of a pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis</p>\n<p>Persistent pulmonary hypertension of the newborn syndrome</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Group 2</strong></p>\n<p><strong>Pulmonary hypertension associated with left heart disease </strong></p>\n</td>\n<td>\n<p>Left ventricular systolic or diastolic dysfunction</p>\n<p>Valvular heart disease</p>\n<p>Congenital cardiomyopathies</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Group 3</strong></p>\n<p><strong>Pulmonary hypertension associated with lung</strong> <strong>disease</strong></p>\n</td>\n<td>\n<p>Chronic obstructive pulmonary disease</p>\n<p>Interstitial lung disease</p>\n<p>Sleep-disordered breathing</p>\n<p>Alveolar hypoventilation disorders</p>\n<p>Chronic exposure to high altitude</p>\n<p>Developmental lung disorders</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Group 4</strong></p>\n<p><strong>Chronic thromboembolic pulmonary hypertension</strong></p>\n</td>\n<td>\n<p>Chronic thromboembolic pulmonary hypertension</p>\n<p>Congenital pulmonary artery stenosis</p>\n<p>Pulmonary arteritis</p>\n<p>Pulmonary angiosarcoma&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Group 5</strong></p>\n<p><strong>Pulmonary hypertension with unclear and/or multifactorial mechanisms</strong></p>\n</td>\n<td>\n<p>Hematological disorders (chronic hemolytic anemias)</p>\n<p>Metabolic disorders (glycogen storage diseases)</p>\n<p>Systemic disorders (sarcoidosis)</p>\n<p>Others (tumor obstruction, fibrosing mediastinitis)</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3729",
      "difficulty": "medium"
    },
    {
      "text": "Which among the following is not a feature of pulmonary arterial hypertension?",
      "choices": [
        {
          "id": 1,
          "text": "Mean pulmonary arterial pressure >20 mm Hg"
        },
        {
          "id": 2,
          "text": "Pulmonary capillary wedge pressure ≤ 25 mm Hg"
        },
        {
          "id": 3,
          "text": "Left atrial pressure ≤ 15 mm Hg"
        },
        {
          "id": 4,
          "text": "Pulmonary vascular resistance ≥ 3 Wood units"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Pulmonary capillary wedge pressure (<strong>PCWP</strong>)&nbsp;<strong>&le; 15 mm Hg</strong> is a feature of pulmonary arterial hypertension (<strong>PAH</strong>).</p>\n<p>The table below shows the hemodynamic classification of pulmonary hypertension. PAH belongs to <strong>WHO group 1</strong>.</p>\n<table>\n<tbody>\n<tr>\n<td>Parameters</td>\n<td>\n<p>Pre-capillary</p>\n<p>WHO groups <strong>1</strong>,3,4,5</p>\n</td>\n<td>\n<p>Post-capillary</p>\n<p>WHO group 2</p>\n</td>\n<td>\n<p>Combined pre and post-capillary&nbsp;</p>\n<p>WHO groups 2,5</p>\n</td>\n</tr>\n<tr>\n<td>mPAP (mmHg)</td>\n<td>&gt;20</td>\n<td>&gt;20</td>\n<td>&gt;20</td>\n</tr>\n<tr>\n<td>PCWP (mmHg)</td>\n<td>&le;15&nbsp;</td>\n<td>&gt;15</td>\n<td>&gt;15</td>\n</tr>\n<tr>\n<td>PVR (wood units)</td>\n<td>&ge;3</td>\n<td>&lt;3</td>\n<td>&ge;3</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>mPAP- Mean pulmonary artery pressure</p>\n<p>PCWP-Pulmonary capillary wedge pressure</p>\n<p>PVR-&nbsp;Pulmonary vascular resistance</p><hr><h3>Related Pearl: Classification of Pulmonary Hypertension & its Causes</h3><p>Based on underlying mechanisms, the World Health Organization has classified pulmonary hypertension into five groups.</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Classification</strong></p>\n</td>\n<td>\n<p><strong>Causes</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Group 1</strong></p>\n<p><strong>Pulmonary arterial hypertension (PAH)</strong></p>\n</td>\n<td>\n<p>Idiopathic PAH</p>\n<p>Hereditary PAH - BMPR2 gene (most common mutation)</p>\n<p>Drug or toxin-induced PAH</p>\n<p>PAH associated with</p>\n<ul>\n<li>Connective tissue disorder (limited systemic sclerosis)</li>\n<li>Portal hypertension</li>\n<li>HIV</li>\n<li>Schistosomiasis</li>\n<li>Congenital heart diseases</li>\n</ul>\n<p>PAH long-term responders to calcium channel blockers</p>\n<p>PAH with overt features of a pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis</p>\n<p>Persistent pulmonary hypertension of the newborn syndrome</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Group 2</strong></p>\n<p><strong>Pulmonary hypertension associated with left heart disease </strong></p>\n</td>\n<td>\n<p>Left ventricular systolic or diastolic dysfunction</p>\n<p>Valvular heart disease</p>\n<p>Congenital cardiomyopathies</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Group 3</strong></p>\n<p><strong>Pulmonary hypertension associated with lung</strong> <strong>disease</strong></p>\n</td>\n<td>\n<p>Chronic obstructive pulmonary disease</p>\n<p>Interstitial lung disease</p>\n<p>Sleep-disordered breathing</p>\n<p>Alveolar hypoventilation disorders</p>\n<p>Chronic exposure to high altitude</p>\n<p>Developmental lung disorders</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Group 4</strong></p>\n<p><strong>Chronic thromboembolic pulmonary hypertension</strong></p>\n</td>\n<td>\n<p>Chronic thromboembolic pulmonary hypertension</p>\n<p>Congenital pulmonary artery stenosis</p>\n<p>Pulmonary arteritis</p>\n<p>Pulmonary angiosarcoma&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Group 5</strong></p>\n<p><strong>Pulmonary hypertension with unclear and/or multifactorial mechanisms</strong></p>\n</td>\n<td>\n<p>Hematological disorders (chronic hemolytic anemias)</p>\n<p>Metabolic disorders (glycogen storage diseases)</p>\n<p>Systemic disorders (sarcoidosis)</p>\n<p>Others (tumor obstruction, fibrosing mediastinitis)</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3727",
      "difficulty": "medium"
    },
    {
      "text": "In a patient diagnosed with pulmonary hypertension, which of the following is an unlikely finding on a chest X-ray?",
      "choices": [
        {
          "id": 1,
          "text": "Enlarged central pulmonary artery"
        },
        {
          "id": 2,
          "text": "Pruning of distal pulmonary vasculature"
        },
        {
          "id": 3,
          "text": "Right ventricular enlargement"
        },
        {
          "id": 4,
          "text": "Focal area of oligemia"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>A focal area of oligemia or Westermark's sign is seen in pulmonary embolism.</p>\n<p>The <strong>signs</strong> seen on chest <strong>radiograph</strong> in <strong>pulmonary</strong> <strong>hypertension</strong> are:</p>\n<ul>\n<li>Enlargement of central pulmonary arteries</li>\n<li>Rapid tapering of vessels known as vascular pruning</li>\n<li>Right ventricular enlargement</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/5a3eaa1db3454c32a80dd6db20bf8c1bx1280x1298.JPEG\" alt=\"Explanation Image\"><p>The ECG shows features of RV strain in patients with PH. The pulmonary function tests show a reduction in DLCO in PAH.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3726",
      "difficulty": "medium"
    },
    {
      "text": "Echocardiography was done for a patient who presented with severe exertional dyspnea, chest pain, and occasional fainting spells. It revealed a mitral valve area of 1 sq cm, elevated LA pressure, and significant RV hypertrophy with TR. Which is the next best step in the evaluation of this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Cardiac MRI"
        },
        {
          "id": 2,
          "text": "CT pulmonary angiography"
        },
        {
          "id": 3,
          "text": "Right heart catheterization"
        },
        {
          "id": 4,
          "text": "Ventilation / perfusion scan"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>In the given scenario, a <strong>mitral valve area</strong> of <strong>1 sq cm</strong> suggests severe <strong>mitral stenosis</strong>. This leads to <strong>elevated LA pressure</strong> and subsequently <strong>pulmonary hypertension</strong>. Due to pulmonary hypertension, there is compensatory RV hypertrophy (right ventricular-pulmonary hypertension coupling) and secondary TR. The next step should be to confirm pulmonary hypertension. <strong>R</strong><strong>ight heart catheterization</strong> is the <strong>gold standard</strong>&nbsp;test for diagnosing pulmonary hypertension.</p>\n<p>Option A: Cardiac MRI is considered the gold standard for assessing RV function. In the case of pulmonary hypertension, it is used for serial follow-ups due to its non-invasive nature.</p>\n<p>Options B and D: CT angiography and ventilation/perfusion scan are done when pulmonary hypertension is suspected to be due to pulmonary embolism, coagulation disorders, or past history of thrombosis (chronic thromboembolic pulmonary hypertension) which should be followed by right heart catheterization.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3725",
      "difficulty": "medium"
    },
    {
      "text": "A 32-year-old female patient presents with gradually worsening shortness of breath, fatigue, and exertional chest pain. On auscultation, a loud P2 is heard. Pulmonary function tests reveal an isolated reduction in DLCO.  Her family history is positive for similar findings in other members and genetic testing has revealed a mutation in the BMPR2 gene. Based on suspicion, which of the following therapies is this patient most likely to benefit from?",
      "choices": [
        {
          "id": 1,
          "text": "Bronchodilator"
        },
        {
          "id": 2,
          "text": "Vasodilator"
        },
        {
          "id": 3,
          "text": "Nitric oxide inhibitor"
        },
        {
          "id": 4,
          "text": "Immunosuppressants"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given clinical scenario suggests a diagnosis of <strong>pulmonary arterial hypertension</strong>. <strong>Vasodilator</strong> therapy would be beneficial in this patient.&nbsp;Endothelin receptor antagonists, PDE-5 inhibitors, and prostacyclins are examples of vasodilators.</p>\n<p>Option A: Since pulmonary arterial hypertension is a vascular disorder, bronchodilation is not beneficial.</p>\n<p>Option C: Nitric oxide is a vasodilator and inhibitors of nitric oxide would worsen the disease in pulmonary arterial hypertension.</p>\n<p>Option D: Immunosuppressants are not useful in pulmonary arterial hypertension.</p><hr><h3>Related Pearl: Drugs used in Pulmonary Arterial Hypertension (PAH)</h3><table>\n<tbody>\n<tr>\n<td><strong>Drug Class</strong></td>\n<td><strong>Examples</strong></td>\n</tr>\n<tr>\n<td>Prostacyclin derivative</td>\n<td>\n<p>Epoprostenol</p>\n<p>Iloprost</p>\n<p>Treprostinil</p>\n</td>\n</tr>\n<tr>\n<td>Endothelin receptor antagonist</td>\n<td>\n<p>Bosentan</p>\n<p>Ambrisentan</p>\n<p>Macitentan</p>\n</td>\n</tr>\n<tr>\n<td>PDE5 inhibitor</td>\n<td>\n<p>Sildenafil</p>\n<p>Tadalafil</p>\n</td>\n</tr>\n<tr>\n<td>Soluble guanyl cyclase stimulator</td>\n<td>Riociguat</td>\n</tr>\n<tr>\n<td>Calcium channel blocker</td>\n<td>\n<p>Nifedipine</p>\n<p>Diltiazem</p>\n<p>Amlodipine</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3724",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following group of drugs can not be used in the management of a patient with pulmonary arterial hypertension?",
      "choices": [
        {
          "id": 1,
          "text": "Phosphodiesterase type-5 inhibitors"
        },
        {
          "id": 2,
          "text": "Prostacyclin derivatives"
        },
        {
          "id": 3,
          "text": "ACE inhibitors"
        },
        {
          "id": 4,
          "text": "Endothelin receptor antagonists"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>ACE inhibitors are not used in pulmonary arterial hypertension.</p><hr><h3>Related Pearl: Drugs used in Pulmonary Arterial Hypertension (PAH)</h3><table>\n<tbody>\n<tr>\n<td><strong>Drug Class</strong></td>\n<td><strong>Examples</strong></td>\n</tr>\n<tr>\n<td>Prostacyclin derivative</td>\n<td>\n<p>Epoprostenol</p>\n<p>Iloprost</p>\n<p>Treprostinil</p>\n</td>\n</tr>\n<tr>\n<td>Endothelin receptor antagonist</td>\n<td>\n<p>Bosentan</p>\n<p>Ambrisentan</p>\n<p>Macitentan</p>\n</td>\n</tr>\n<tr>\n<td>PDE5 inhibitor</td>\n<td>\n<p>Sildenafil</p>\n<p>Tadalafil</p>\n</td>\n</tr>\n<tr>\n<td>Soluble guanyl cyclase stimulator</td>\n<td>Riociguat</td>\n</tr>\n<tr>\n<td>Calcium channel blocker</td>\n<td>\n<p>Nifedipine</p>\n<p>Diltiazem</p>\n<p>Amlodipine</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3732",
      "difficulty": "easy"
    }
  ]
}